BIRC5 and neoplasm: A single-cell study of ibrutinib-treated MCL patients also found transcriptionally heterogeneous subpopulations within the same resistant tumor, which gained chr17q amplifications and resulted in elevating BIRC5 expression, which may lead to tumor cell proliferation.35